Rekah Pharmaceutical Industry Ltd (TA:REKA) — Market Cap & Net Worth
Market Cap & Net Worth: Rekah Pharmaceutical Industry Ltd (REKA)
Rekah Pharmaceutical Industry Ltd (TA:REKA) has a market capitalization of $33.60 Million (ILA12.53 Billion) as of July 24, 2026. Listed on the TA stock exchange, this Israel-based company holds position #23362 globally and #325 in its home market, demonstrating a 6.60% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rekah Pharmaceutical Industry Ltd's stock price ILA1098.00 by its total outstanding shares 11414636 (11.41 Million). See Rekah Pharmaceutical Industry Ltd capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Rekah Pharmaceutical Industry Ltd Market Cap History: 2015 to 2026
Rekah Pharmaceutical Industry Ltd's market capitalization history from 2015 to 2026. Data shows change from $51.97 Million to $33.60 Million (-4.35% CAGR).
Rekah Pharmaceutical Industry Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rekah Pharmaceutical Industry Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.11x
Rekah Pharmaceutical Industry Ltd's market cap is 0.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $63.84 Million | $218.38 Million | -$11.00 Million | 0.29x | N/A |
| 2017 | $109.18 Million | $208.18 Million | -$22.48 Million | 0.52x | N/A |
| 2018 | $78.77 Million | $207.83 Million | $7.03 Million | 0.38x | 11.21x |
| 2019 | $61.09 Million | $196.50 Million | $3.86 Million | 0.31x | 15.81x |
| 2020 | $81.98 Million | $265.47 Million | $10.80 Million | 0.31x | 7.59x |
| 2021 | $71.22 Million | $263.95 Million | $6.62 Million | 0.27x | 10.75x |
| 2022 | $46.88 Million | $292.39 Million | -$2.04 Million | 0.16x | N/A |
| 2023 | $44.37 Million | $321.66 Million | -$6.91 Million | 0.14x | N/A |
| 2024 | $40.70 Million | $321.71 Million | $6.21 Million | 0.13x | 6.56x |
| 2025 | $33.42 Million | $300.99 Million | -$18.07 Million | 0.11x | N/A |
Competitor Companies of REKA by Market Capitalization
Companies near Rekah Pharmaceutical Industry Ltd in the global market cap rankings as of July 24, 2026.
Key companies related to Rekah Pharmaceutical Industry Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #508 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $51.26 Billion USD ( CN¥350.27 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.61 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #508 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $51.26 Billion | CN¥54.91 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.61 Billion | $41.45 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.60 |
Rekah Pharmaceutical Industry Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Rekah Pharmaceutical Industry Ltd's market cap moved from $51.97 Million to $ 33.60 Million, with a yearly change of -4.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA33.60 Million | +0.55% |
| 2025 | ILA33.42 Million | -17.89% |
| 2024 | ILA40.70 Million | -8.28% |
| 2023 | ILA44.37 Million | -5.35% |
| 2022 | ILA46.88 Million | -34.17% |
| 2021 | ILA71.22 Million | -13.13% |
| 2020 | ILA81.98 Million | +34.20% |
| 2019 | ILA61.09 Million | -22.45% |
| 2018 | ILA78.77 Million | -27.85% |
| 2017 | ILA109.18 Million | +71.01% |
| 2016 | ILA63.84 Million | +22.84% |
| 2015 | ILA51.97 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 24th, 2026 the market cap of Rekah Pharmaceutical Industry Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $33.60 Million USD |
| MoneyControl | $33.60 Million USD |
| MarketWatch | $33.60 Million USD |
| marketcap.company | $33.60 Million USD |
| Reuters | $33.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rekah Pharmaceutical Industry Ltd
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeut… Read more